Logo image
The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States
Journal article   Open access   Peer reviewed

The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States

Colleen S. Kraft, Angela L. Hewlett, Scott Koepsell, Anne M. Winkler, Christopher J. Kratochvil, LuAnn Larson, Jay B. Varkey, Aneesh K. Mehta, Marshall Lyon, Rachel J. Friedman-Moraco, …
Clinical infectious diseases, Vol.61(4), pp.496-502
08/15/2015
DOI: 10.1093/cid/civ334
PMCID: PMC4542597
PMID: 25904375
url
https://doi.org/10.1093/cid/civ334View
Published (Version of record) Open Access

Abstract

Background. The current West Africa Ebola virus disease (EVD) outbreak has resulted in multiple individuals being medically evacuated to other countries for clinical management. Methods. We report two patients who were transported from West Africa to the United States for treatment of EVD. Both patients received aggressive supportive care measures, as well as an investigational therapeutic (TKM-100802) and convalescent plasma. Results. While one patient experienced critical illness with multi-organ failure requiring mechanical ventilation and renal replacement therapy, both patients recovered without serious long-term sequelae to date. Conclusions. It is unclear what role the experimental drug and convalescent plasma had in the recovery of these patients. Prospective clinical trials are needed to delineate the role of investigational therapies in the care of patients with EVD.
Immunology Infectious Diseases Microbiology Life Sciences & Biomedicine Science & Technology

Details

Metrics

Logo image